The news: Oura and LillyDirect teamed up to offer anyone who signs up for the drugmaker's online platform a free Oura Ring sizing kit (a $10 value). The partnership is primarily geared toward GLP-1 patients, for now: LillyDirect refers eligible users to Oura, and those who purchase an Oura Ring gain access to GLP-1-specific features in the Oura app to help track their treatment progress. The two companies will not share consumer data.

For context, last month, Oura introduced GLP-1 Insights, a companion feature in its app that combines biometric tracking with dosing schedules, weight and body changes, and other health signals relevant to Oura members on these medications.

Why it matters: The partnership gives Oura a chance to convert LillyDirect's GLP-1 users into customers. While a free ring sizing kit isn't the same as a free device, people who receive and try the kit are more likely to purchase a ring than those who never do. That could expose Oura to a rapidly expanding pool of consumers as more patients turn to LillyDirect's self-pay channel for weight loss drugs.

The Oura ring is already being used at scale by GLP-1 patients, which could be a built-in proof point to the target audience within LilyDirect. More than half of Oura members identify as overweight or having obesity, and tens of thousands already log their GLP-1 therapy in the app, according to Oura.

For Lilly, this is a retention and adherence play. Among obesity patients who fill an initial GLP-1 prescription, only 32% are still taking the medication 13 months later, according to IQVIA. Patients who use Oura's health tracking and AI coaching to monitor metrics and build habits around sleep, muscle preservation, and recovery may be more likely to stay on long-term maintenance therapy.

Implications for pharma and digital health: Pharma is repositioning weight loss drugs as long-term maintenance medications rather than short-term cures, and that pivot hinges on adherence. Partnerships with digital platforms give drugmakers a lever to help defend medication adherence. We expect this model to extend across other therapeutic areas, especially if drugmakers can show that building support ecosystems around their medications boosts long-term patient retention.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.